To address the challenges in understanding specific immune mechanisms related to recurrent implantation failure (RIF) and recurrent pregnancy loss (RPL) and propose a framework for immune profiling.
Key Findings:
Persistent Th1 dominance and inadequate tolerance induction can lead to RIF and RPL, impacting treatment strategies.
Clinical translation of reproductive immunology is hindered by heterogeneity in assays and mistimed immune assessments, leading to inconsistent outcomes.
A subset of patients may exhibit immune dysregulation that requires precise identification and targeted intervention to improve clinical outcomes.
Interpretation:
Successful implantation relies on coordinated immune adaptation, and disruptions in this process can lead to reproductive failure. The ERIF aims to provide a structured approach to understanding these dynamics and their clinical applications.
Limitations:
The framework is hypothesis-generating and not yet validated as a clinical algorithm, requiring further research.
Requires exclusion of non-immune factors, such as chronic endometritis or microbiome imbalances, before immune profiling can be accurately conducted.
Conclusion:
The ERIF offers a conceptual model to improve the understanding and management of immune-related reproductive failures, emphasizing the need for phenotype-stratified clinical trials to advance reproductive immunology.
A two-marker methylated DNA assay identified endometrial cancer with 96% sensitivity in self-collected vaginal fluid — but prospective validation is needed before it can reduce biopsies in routine care.
